2012’s Top Biopharma Dealmakers
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca was the top in-licenser, snagging a $3.4 billion pact with BMS for Amylin’s diabetes assets, making metabolic diseases the leading therapeutic area in biopharma alliances.